TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Posterior Wall And Left Atrial Appendage Empiric Electrical Isolation for Non-Paroxysmal Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed and dated informed consent form~2. Stated willingness to comply with all study procedures and availability for the duration of the study~3. Male or female, aged 18 or greater~4. In good general health as evidenced by medical history and diagnosed with symptomatic persistent AF or long-standing persistent AF.~   1. Persistent AF will be defined as a sustained episode lasting \> 7 days and less than 1 year.~  2. Long-standing persistent AF will be defined as a sustained episode lasting more than 1 year and less than 10 years.~  3. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms, or any combination of the above.~5. At least one episode of persistent AF must have been documented by ECG, Holter, loop recorder, ziopatch, telemetry, trans telephonic monitoring (TTM), or implantable device within last 10 years of enrollment in this investigation.~6. Patients undergoing first time procedure for AF.~Exclusion Criteria:~1. Patients with paroxysmal AF.~   • Paroxysmal AF will be defined as a sustained episode lasting \< 7 days (either terminated spontaneously or with pharmacological or electrical cardioversion.~2. Reversible causes of AF.~3. Patients with contraindications to systemic anticoagulation with heparin or coumadin, direct thrombin inhibitor or factor Xa inhibitors.~4. Patients with left atrial size ≥ 75 mm (2D echocardiography, parasternal long axis view)~5. Left atrial or LAA thrombus~6. Patients with severe valvular heart disease or after mitral valve replacement (bioprosthetic or mechanical).~7. Patients with a life expectancy ≤ 24 months~8. CHA2DS2Vasc score of 0 for men and CHA2DS2Vasc score of 1 for women.~9. Patients who are pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- PVI (Type: ACTIVE_COMPARATOR): Pulmonary vein isolation alone will be performed using radiofrequency energy
- PVI + PWI (Type: EXPERIMENTAL): Pulmonary vein isolation plus posterior wall isolation will be performed using radiofrequency energy
- PVI + PWI + LAAEI (Type: EXPERIMENTAL): Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation will be performed using radiofrequency energy
- PVI + PWI + LAAEI + CSI (Type: EXPERIMENTAL): Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation plus coronary sinus isolation will be performed using radiofrequency energy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient should fully know and understand the content of consent form, and the patient is willing and able to sign an informed consent form~* Chinese outpatients with confirmed T2DM~* Patients of ≥ 18, \< 80 years old~* Patients currently use metformin monotherapy ≥ 1500 mg/day or maximum tolerable dose and whose glucose levels are not adequately controlled~* HbA1c ≥ 7% and \< 12%~* New user\* linagliptin or acarbose as combination therapy with metformin ≥ 1500 mg/day or maximum tolerable dose \*New user defined as a T2DM patient initiating linagliptin or acarbose as an add-on therapy.~These are patients who are on metformin and whose glucose levels are not adequately controlled.~Exclusion Criteria:~* Type 2 diabetes mellitus patients who previously used any DPP-4 inhibitor/ GLP-1 receptor agonist at index date or any AGI at index date, are not eligible to participate. Also excluded are patients who currently using any glucose-lowering agent as monotherapy other than metformin.~* Patients with clinically significant acute major organ or systemic disease or other condition judged by the investigator that would create difficulty for the 24-week follow-up.~* Patients who participated in a clinical trial within 2 months prior to study enrolment date.~* Patients diagnosed with Type 1 diabetes mellitus, secondary diabetes or gestational diabetes.~* Current treatment with systemic steroids at time of informed consent or within 6 weeks prior to informed consent.~* Patients with known significant GI disease as judged by the study physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin Initiators (Type: None): None
- Acarbose Initiators (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-cancer Pain and Cognitive Impairment: A Disabling Relationship

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age over 65~2. Pain at least 3 months duration~3. Pain greater in lower extremity than other anatomical site with ambulation~4. Pain self-report of moderate intensity of higher on an average day~5. Community-dwelling~6. Ambulatory~7. Physician states participants have decision-making capacity to enroll into the trial~8. Participants with cognitive impairment have a reliable caregiver~9. Inadequate pain relief from NSAIDS and/or acetaminophen in the past~Exclusion Criteria:~1. Current cancer requiring chemotherapy~2. History of addiction to opioids or other controlled substance~3. Consumes more than 2 alcoholic drinks a day~4. Severe balance disturbance~5. Intra-articular steroid injection in the past 6 weeks

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acetaminophen (Type: ACTIVE_COMPARATOR): None
- Long Acting Oxycodone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pelvic Alignment Level (PAL) Instrument Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has signed an IRB approved, evaluation specific Informed Patient Consent Form.~* Patient is a male or non-pregnant female age 18 years or older at time of enrollment.~* Patient clinically qualifies for total hip arthroplastic surgery, based on physical examination and medical history.~* Patient must have a diagnosis of: osteoarthritis, traumatic arthritis, avascular necrosis, slipped capital epiphysis, pelvic fracture, failed fracture fixation or rheumatoid arthritis.~Exclusion Criteria:~* Patient's anatomy precludes a cup placement of 45° inclination and 20° anteversion.~* Patient has an active infection within the affected hip joint.~* Patient is a prisoner.~* Patient has plans to relocate to another geographic area before the completion of the evaluation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pelvic Alignment Level (PAL) (Type: OTHER): Pelvic Alignment Level Instrument Used
- No Pelvic Alignment Level (PAL) (Type: OTHER): No Pelvic Alignment Level Instrument Used

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with advanced solid tumors or relapses/refractory non-Hodgkin's lymphoma confirmed by histology or cytology~* Has at least one measurable lesion (solid tumor according to RECIST v1.1 criteria, non-Hodgkin's lymphoma according to Lugnao criteria)~* ECOG score of 0 or 1;~* Expected survival time ≥ 3 months (at the discretion of the investigator);~* Adequate organ and bone marrow function;~* Voluntarily sign the informed consent form;~Exclusion Criteria:~* Has central nervous system primary malignant tumor, active epileptic seizure, spinal cord compression or carcinomatous meningitis~* The previous anti-tumor treatment has not passed the prescribed washout period~* HIV antibody is positive, or with other acquired/congenital immunodeficiency disease, or with history of organ transplantation;~* Active hepatitis B or hepatitis C virus (HCV) antibody was positive;~* Patients who are pregnant or lactating;~* Known or suspected hypersensitivity to the study drug or its pharmaceutical excipients (including mono-hydrate citric acid, sodium di-hydrate citric acid, mannitol, polysorbate, arginine, succinic acid);~* Any active autoimmune disease, or known history of autoimmune disease, or syndrome requiring systemic steroids or immunosuppressive medications (other than controlled thyroid disease with alternative therapy/non-immunosuppressive therapy);~* Participation in another therapeutic or interventional clinical study in the meantime;~* Other circumstances where the investigator considers it is not appropriate to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ADG106 combined with PD-1 antibody Dose Escalation Level 1 (Type: EXPERIMENTAL): None
- ADG106 combined with anti PD-1 antibody Dose Escalation Level 2 (Type: EXPERIMENTAL): None
- ADG106 combined with anti PD-1 antibody Expansion Phase (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women must have newly diagnosed histologically or cytologically confirmed endometrial cancer~* Women should have received no prior therapy for their disease~* Women who are planning to undergo hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy for the management of their endometrial cancer~* Women must have the ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Women who are receiving any other investigational agents~* Women with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to isosulfan blue or indocyanine green or other agents used in this study~* Women with hypersensitivity to phenylmethane compounds, or a history of allergic reaction to iodides~* Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Women with a history of prior loop electrosurgical excision procedure (LEEP) or cone procedures performed on their cervix~* Women with a history of lymphedema, lymphoma, or lymphatic hyperplasia (Castleman disease)~* Women with a history of a prior malignancy~* Women may also be excluded at the discretion of their surgeon if he or she feels that the patient is not an appropriate candidate

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (SLN mapping, biopsy, surgery) (Type: EXPERIMENTAL): Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 3 Direct Laryngoscopes for Tracheal Intubation in Patients Undergoing Lumbar Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
A. Inclusion Criteria:~1. Patients undergoing lumbar spine surgery procedures under general anesthesia~2. Patients with a documented BMI of \<35~3. Willingness and ability to sign an informed consent document~4. 18 - 80 years of age of either gender~5. American Society of Anesthesiologists (ASA) physical status classification I - II or III~B. Exclusion Criteria:~1. Patients who are deemed to be such a significant of an airway risk that they necessitate awake fiberoptic intubation or a difficult tracheal intubation is anticipated~2. Patients with history of difficult intubation~3. Patients with oxygen saturation less than 95% at room air~4. Patients with history facial abnormalities, oral-pharyngeal cancer or reconstructive surgery~5. Any pathologies of the mouth, pharynx or larynx, or the access to the airway is restricted~6. Patients with Immobilized cervical spine, or history of cervical abnormalities~7. Patients with a history of uncontrolled gastroesophageal reflux, hiatus hernia or diabetic gastroparesis~8. Any coagulation disorder~9. Pregnant patients~10. Emergency surgeries~11. Any other conditions or use of any medication which may interfere with the conduct of the Study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Blade MAC size 3 (Type: ACTIVE_COMPARATOR): Patient will be intubated using a:~Direct Laryngoscope (DL) Mac size 3 (Sun-Med GreenLine®/D™ Macintosh)
- Blade MAC size 3.5 (Type: ACTIVE_COMPARATOR): Patient will be intubated using a:~DL-blade mac size 3.5 (Sun-Med Greenline®/D™ Macintosh)
- Inscope Blade size 3.5 (Type: EXPERIMENTAL): Patient will be intubated using a:~Inscope DL-blade size 3.5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Cardiac Monitoring in Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-50 years with ability to consent.~2. No primary cardiac abnormality.~3. Ability to receive an implantable loop recorder and tolerate the procedure.~4. Patients with epilepsy as described by the three groups (intractable focal epilepsy, controlled focal epilepsy and symptomatic generalized epilepsy)~Exclusion Criteria:~1. Cardiac disease of any type~2. Known epilepsy genetic disorder with potential cardiac compromise~3. Major co-morbidities such as cancer, diabetes, stroke, bleeding disorder~4. Chronic psychosis~5. Severe MR without reliable caregiver monitoring (what is MR?)~6. Already included in another clinical trial that will affect the objectives of this study.~7. Life expectancy is less than 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- LINQ ICM (Type: EXPERIMENTAL): The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population. The LINQ ICM is approved by the FDA for use in patients where there is a suspicion of occult cardiac arrhythmias and is therefore being utilized in this study in accordance with the FDA labeling.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Breastfeeding Infants Receiving Respiratory Support Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Infants cared for at Imperial College Healthcare NHS trust neonatal unit at Queen Charlottes and Chelsea Hospital and St Marys Hospital. Infants will be eligible if they are over 30 weeks of gestational age and receive continuous treatment with nCPAP or HHFNC .~Exclusion Criteria:~* Major congenital malformation or underlying genetic disorder~* signs of severe progressive respiratory distress~* FiO2 \> 0.4~* PCo2 \> 9kPa~* Need for high CPAP \> 8cmH2O~* Need for HHFNC with flow rate of \>8litres/min~* Severe temperature instability, not tolerating 30 min outside the incubator~* CPAP or HHFNC treatment stopped

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CPAP group (Type: None): 25 infants undergoing treatment with continuous nCPAP who are making attempts at breast feeding and receiving nasogastric feeds.
- HHFNC group (Type: None): 25 infants undergoing treatment with continuous HHFNC oxygen who are making attempts at breast feeding and receiving nasogastric feeds.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18~2. Subject willing and able to give informed consent.~3. Adult patients with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.~4. PASI \> 10 and BSA affected with psoriasis \> 10.~5. Abdominal obesity defined by waist hip ratio \> 0.90 for men and \> 0.85 for women and BMI ³ 30 kg/m2~Exclusion Criteria:~* On insulin or other diabetes (anti-hyperglycemic) medication~* Congestive Heart Failure~* Heart Attack, Stroke or Transient Ischemic Attack in last 3 months~* Unstable angina~* Pulmonary disease requiring oxygen~* SLE, optic neuritis, transverse myelitis, epilepsy~* Positive PPD~* Scheduled for upcoming surgery~* Known immunosuppression (for example, HIV)~* Known autoimmune disease~* Hepatitis B or Hepatitis C~* Pregnant or nursing~* Renal insufficiency (Creatinine \>1.5)~* Latex allergy~* Use of live vaccination in past 90 days~* Organ transplantation~* History of severe infection~* History of malignancy (except cured non-melanoma skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etanercept (Type: EXPERIMENTAL): Etanercept

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electrotherapy in the Management of Myofascial Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female who had first breast cancer surgery, regardless of the type of surgery~* Age ≥ 18 years~* Patients with refractory pain with myofascial syndrome, with a numerical scale ≥ 4~* Topical treatment for refractory pain completed more than 30 days ago~* Healthy, non-irritated skin on painful areas to treat~* Patient with a third party who can attend visits M0 and M2.5~* Obtaining the signed written consent of the patient~* Major patient affiliated to a social security scheme~Exclusion Criteria:~* Patient who has used TENS before on the muscles affected by the myofascial syndrome~* Post-surgery management of the affected area by a physiotherapist~* Person with venous thrombosis~* Contraindications specific to the treatments studied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TENS / TENS ECOMODYN (Type: OTHER): Patients who have signed their consent receive, after randomization, the trial treatments assigned to them. Arm TENS / TENS ECOMODYN Patients first start with TENS during 2 months puis change with TENS ECOMODYN during 2 months with a wash-out period of 15 days
- TENS ECOMODYN / TENS (Type: OTHER): Patients who have signed their consent receive, after randomization, the trial treatments assigned to them. Arm TENS ECOMODYN / TENS Patients first start with TENS ECOMODYN during 2 months puis change with TENS during 2 months with a wash-out period of 15 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Improved Diagnosis of Peritoneal Dialysis Peritonitis by Calorimetry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* all patients on peritoneal dialysis~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues